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Background: The Equivital (EQ02) is a multi-parameter telemetric device offering
both real-time and/or retrospective, synchronized monitoring of ECG, HR, and HRV,
respiration, activity, and temperature. Unlike the Holter, which is the gold standard
for continuous ECG measurement, EQO2 continuously monitors ECG via electrodes
interwoven in the textile of a wearable belt.
Objective: To compare EQ02 with the Holter for continuous home measurement of
ECG, heart rate (HR), and heart rate variability (HRV).
Methods: Eighteen healthy participants wore, simultaneously for 24 h, the Holter and
EQ02 monitors. Per participant, averaged HR, and HRV per 5 min from the two devices
were compared using Pearson correlation, paired T-test, and Bland-Altman analyses.
Accuracy and precision metrics included mean absolute relative difference (MARD).
Results: Artifact content of EQ02 data varied widely between (range 1.93–56.45%) and
within (range 0.75–9.61%) participants. Comparing the EQ02 to the Holter, the Pearson
correlations were respectively 0.724, 0.955, and 0.997 for datasets containing all data
and data with <50 or <20% artifacts respectively. For datasets containing respectively
all data, data with <50, or <20% artifacts, bias estimated by Bland-Altman analysis
was −2.8, −1.0, and −0.8 beats per minute and 24 h MARD was 7.08, 3.01, and 1.5.
After selecting a 3-h stretch of data containing 1.15% artifacts, Pearson correlation was
0.786 for HRV measured as standard deviation of NN intervals (SDNN).
Conclusions: Although the EQ02 can accurately measure ECG and HRV, its accuracy
and precision is highly dependent on artifact content. This is a limitation for clinical
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use in individual patients. However, the advantages of the EQ02 (ability to simultaneously
monitor several physiologic parameters) may outweigh its disadvantages (higher artifact
load) for research purposes and/ or for home monitoring in larger groups of study
participants. Further studies can be aimed at minimizing the artifacts.
Keywords: ECG, Equivital-EQ02, Holter electrocardiogram, remote monitoring, validation study, heart rate, heart
rate variability (HRV), ECG artifact processing
INTRODUCTION
With cardiovascular diseases still representing a leading cause
of death globally, continuous electrocardiography (ECG)
measurement is becoming increasingly important. Continuous
ECG measurements yields valuable information on heart rate
(HR) and its variability (HRV) that can be measured at a
beat-to-beat level. Their direct clinical importance has been
demonstrated in numerous studies. HR is a major risk factor for
morbidity and mortality in cardiovascular diseases (Diaz et al.,
2005; Hjalmarson, 2007). Even in apparently healthy individuals,
HR has predictive value for sudden cardiac death (Mølgaard
et al., 1991). Furthermore, control of HR has become the focus of
drug development for cardiovascular diseases (Routledge et al.,
2002). In addition to HR, continuous measurement of heart
rate variability (HRV) serves as an index of cardiac sympathetic
and parasympathetic activity (Thayer et al., 2010). HR and HRV
associate with cardiac (Mølgaard et al., 1991), physiological
(Tsuji et al., 1994), psychological (Friedman and Thayer, 1998;
Dishman et al., 2000), and sleep-related disorders (Stein and Pu,
2012); and are being used as prognostic indicators for cardiac-
and non-cardiac diseases, such as idiopathic dilated myopathy
(Fauchier et al., 1997), myocardial infarction (La Rovere et al.,
1998), renal failure (Oikawa et al., 2009), end stage renal disease
(Hayano et al., 1999), and cancer (Guo et al., 2015).
ECG signals can be obtained from varying sources, such
as Holter monitoring, bedside monitoring of vital parameters,
systems for surface ECG, ergometric stress tests, and systems
for telemetry (Gulizia et al., 2006). Of these, the Holter monitor
(Holter) is the gold standard for continuous ECG measurement.
The Holter records ECG signals via electrodes attached to the
chest. However, over the years different innovative devices that
are able to comfortably monitor ECG simultaneously with other
physiological parameters for a prolonged period of time in freely
moving subjects have become available. The Equivital EQ02
Lifemonitor (EQ02,) is a convenient and safe wireless ambulatory
device that continuously measures ECG, HR, and HRV via a
Abbreviations: ANN, Average of NN intervals; ARD, Absolute relative difference;
BPM, Beats per minute; ECG, Electrocardiogram; EQ02, Equivital EQ02
lifemonitor; Holter, Holter ambulatory ECG monitor; HR, Heart rate; HRV, Heart
rate variability; MARD, Mean absolute relative difference; ms, Milliseconds; NN,
Normal- to- normal sinus rhythm interval; NN50, Number of adjacent NN
intervals with a difference less than 50ms; pNN50, Ratio of a NN50 to total
number of NN intervals; RD, Relative difference; RR, interval between the R wave
peaks of the recorded QRS complex; RMSSD, Square root of the mean squared
differences of successive intervals; SDNN, Standard deviation of NN intervals;
SDANN, Standard deviation of 5min averages of NN intervals; SDSD, Standard
deviation of successive differences of NN intervals; SDNNi, Mean of the standard
deviation of 5-min NN intervals.
chest-worn sensor belt embedding textile-based electrodes. In
addition to cardiac parameters, EQ02 also measures breathing
rate, body position, and movement (accelerometry), and skin
and core body temperature, all synchronized- and time- stamped
to provide contextual significance for possible diagnostic,
therapeutic, or research purposes. Although EQ02 has been used
in several studies, e.g., for ambulatory monitoring of pilots,
athletes, and military personnel, both under physiological and
extreme environmental conditions (Karlen et al., 2010; Bizzini
et al., 2013; Liu et al., 2013; Tharion et al., 2013), EQ02 has not
yet been validated against the gold standard for measurement of
cardiac parameters.
Here for the first time, we compared the accuracy of EQ02
and Holter for continuous ECG, HR, and HRV monitoring.
The EQ02 and Holter were worn simultaneously for 24 h in
home setting by an heterogeneous group of healthy male and
female volunteers. Results were analyzed in point accuracy
(including absolute and relative differences), monitor reliability,
and precision metrics for both devices.
METHODS
Ethics Statement
This study was approved by the institutional review board
of Leiden University Medical Center (LUMC) under protocol
P11.116. All study participants gave written informed consent.
Study Participants
The present study was embedded in the Switchbox Study,
which was a sub-study of the Leiden Longevity Study (LLS).
The LLS was originally designed to investigate genetic and
phenotypic biomarkers associated with human longevity. Amore
detailed description of the study design and recruitment strategy
for the Switchbox study (Jansen et al., 2015) and the LLS
(Schoenmaker et al., 2006) has been described elsewhere. The
present study population consisted of 18 healthy adult male and
female volunteers from the local population. The only exclusion
criterion was presence of obvious chest deformity, which would
impair lifemonitor belt fitting.
Apart from the 18 subjects, artifact percentage was determined
in all rawHolter recordings that were collected in the department
of Cardiology of the LUMC in 2014. In total, artifact data from
ECG recordings of 4143 persons were used. Apart from the
percentage of artifacts contained in the recordings, no other
data from these individuals were used. Furthermore, similar raw
artifact data were extracted from EQ02 recordings from 200
switchbox participants.
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Experimental Protocol
After body mass index and waist: hip ratio were measured,
participants wore, simultaneously, the EQ02 monitor, a Holter,
and a Fitbit oneTM. These were turned on approximately
concurrently. Participants undertook their usual daily activities,
except swimming. They additionally kept a detailed diary of the
type and timing of all their activities.
Study Devices
EQ02 Monitoring
The EQ02 (Equivital EQ02, Hidalgo, UK) continuouslymeasured
ECG on two channels via three electrodes (Table 1). The EQ02
monitoring system consisted of a LM 1000 Lifemonitor sensor
electronic module (SEM), Lifemonitor belts of varying sizes,
a SEM lead and charging dock, a blue tooth USB dongle for
laptop/ PC, and an Equivital Manager to configure SEMs and to
download and export data. For this study, SEMs were configured
in clinical mode, and data reported retrospectively at local time.
Bluetooth connectivity was disabled and data transmission was at
partial disclosure.
An appropriately sized lifemonitor belt held the SEM onto the
subject’s body. Its textile-based electrodes were moistened with
water before making contact with the participant’s skin. SEMs
were charged for approximately 1 h after 12 h of recording. Upon
study completion, SEM data was uploaded onto the Equivital
manager; from where date- and time- stamped ECG, inter-beat
interval, and summary data of vital signs were extracted and
exported.
Holter ECG Monitoring
The Holter (SEER MC Holter monitor, GE Healthcare, USA)
measured ECG on three channels (Table 1). The Holter consisted
of seven electrodes; color-coded lead wires and a battery
operated, digital ECG recorder. Before placement of electrodes,
participants’ skin were prepared with alcohol and 3M red dot
2236 trace prep (3M Healthcare, Canada) to remove non-
conductive skin layer and reduce skin impedance and eventual
artifacts. Color-coded leads were clipped on to 3M electrodes
(type 2271, 3M Healthcare, Canada) and placed as shown in
Figure 1.
Fitbit OneTM Wireless Activity and Sleep Tracker
The Fitbit oneTM (Fitbit, San Franscisco, USA) was worn on the
waist (belt) during the day for tracking activity (step-counts) and
on the sleep wrist-band at night for tracking sleep length and
number and durations of awakenings. Upon study completion,
data was downloaded via Fitbit dashboard. Sleep efficiency was
extracted as a composite of time to fall asleep, number of
awakenings, and restless periods, total time in bed and the actual
sleep time (Di Rienzo et al., 2013).
Data Management
While data extracted from EQ02 were automatically time- and
date stamped (date, time in hr., min., sec. & ms.), Holter data
were not. Data from both devices were synchronized based on the
Equivital time stamp, by selecting aberrations (non-sinus beats)
in two consecutive heart beats from the Holter that corresponded
to those from EQ02, mostly around the start of the recording.
5-min trends (averages) of HR, RR, and HRV parameters from
synchronized data were then extracted for analysis.
Data Management: Holter Monitor
Holter ECG data were analyzed using MARS ambulatory
Holter ECG analysis system (GE Healthcare, Milwaukee, WI,
USA). After extraction, an exportable file was visible on
MARS, which contained the annotations “N” (normal sinus-
rhythm), “V” (ventricular-beat), “S” (supraventricular-beat), or
“X” (artifact; Figure 1A). The software recognized and grouped
TABLE 1 | Technical characteristics of the EQ02 and Holter monitors.
Holter Equivital (EQ02) lifemonitor
Acceptance Gold standard Relatively new device
Parameters measured ECG only ECG, breathing rate, tri-axial accelerometry, skin temperature, core body
temperature, all fully synchronized.
Data presentation Retrospective Real-time (live) and retrospective (date- and time- stamped).
Recording modes Ambulatory Ambulatory and Clinical
Recording time Usually 24–48 h Fully charged battery lasts 24–48 h*. The internal memory of the recorder stores
up to 50 days of data
Channels 3 2
Electrodes 7 3
Type of electrodes Stick-on Textile electrodes
Skin preparation Necessary (Removal of non-conductive skin layer) None
Convenience Can be cumbersome due to multiple lead wires,
sensor pads, clips and/or re-enforcing tapes,
carry-case
Easy to wear belt
Analysis software MARS Vivosense
Data quality Gold standard High quality P-wave and QRST detection. Accurate and precise ECG, HR and
HRV measurement when artifact content of its recording is <20%
*For this study, the monitors were charged after 12 h of use.
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FIGURE 1 | Analysis software for Holter and EQ02 data management. (A) Shows the Holter monitor including its electrodes, lead wires, and its analytical
software. Annotated tracings from the Holter can be seen on the MARS software. (B) Shows the EQ02 unit, consisting of the lifemonitor belt on which are three
textile-based electrodes. ECG tracings are visualized on the cardiac layout of Vivosense software.
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QRS complexes on similarity. This process was manually checked
and corrected when the recognition of QRS-location was faulty or
the sinus/non-sinus labeling was wrong.
EQ02 Data Management: Vivosense
RawECGdata fromEQ02was analyzed usingVivosensemodular
physiological monitoring and analysis platform (Vivonoetics,
San Diego, USA). EQ02 data were visualized with Cardiac
layout (Figure 1B), for inspecting each ECG channel and
derived R-wave markings, and artifact identification. This layout
also contained accelerometer data channels for contextual
interpretation.
The EQ02 unit provided two leads of ECGmeasurements that
shared a common reference. These were denoted as SEM_ecg1
(primary raw ECG signal) and SEM_ecg2 (secondary raw ECG
signal) respectively. Vivosense processed and performed QRS
detection on both channels to generate two sets of R-wave
markings. We chose SEM_ecg1, which was then scaled, and
filtered by Vivosense, as primary source ECG for derivation of
RR, HR, and HRV parameters.
Artifacts in the ECG signals were identified and annotated.
Artifacts were defined as (i) distorted signals and/ or (ii)
segments of signals in which the different waves of the
ECG complex could not be clearly identified. Vivosense offers
an algorithm that automatically marks and calculates artifact
percentage (Figure 1B), and no-, low-, medium-, and high-
artifact cleaning/ noise reduction options. The automatic artifact-
marking algorithm takes into account the minimum and
maximum allowable heart rates, presence of ectopic beats,
maximal interpolation length, and signal noise. After removal of
charging times, Vivosense automatic cleaning of the data in this
study was performed by selecting the timeframe to be cleaned,
setting the sensitivity level of the automatic cleaning algorithm
at medium noise filtering, and setting the minimal and maximal
allowable HR limits to 30 and 220 beats per minutes respectively.
In addition, complete manual cleaning of EQ02 data was
done for one participant, involving the time-intensive process of
relocating incorrectly automatically recognized QRS-complexes
to correct locations, and manually identifying and excluding
artifacts.
Furthermore, Vivosense software calculated and displayed
eight HRV indices, namely, average of NN-intervals (ANN),
standard deviation of NN-intervals (SDNN), standard deviation
of 5-min averages of NN-intervals (SDANN), standard deviation
of successive differences of NN-intervals (SDSD), square root of
the mean squared differences of successive intervals (RMSSD),
mean of the standard deviation of 5-min NN-intervals (SDNNi),
number of adjacent NN-intervals with a difference less than 50
ms (NN50), and ratio of NN50 to total number of NN-intervals
(pNN50).
Accuracy, Precision, and Reliability Metrics
The point accuracy of EQ02 was measured in terms of the
relative difference (RD) and absolute relative difference (ARD)
of HR measurements to assess respectively the bias (relative
to the Holter) and the average error. The RD was calculated
using the formula [(EQ02 HR—Holter HR)/Holter HR]. The
ARD was calculated using the formula [|EQ02 HR—Holter
HR|/Holter HR]. We additionally determined the mean absolute
relative difference (MARD) of all paired points. The mean and
standard deviation (SD) of MARDs from all 18 participants
were computed for each synchronized 24 h HR measurement,
to assess respectively the accuracy and precision of EQ02 HR
measurements.
Statistical Analysis
Of the original 5182 paired data points of 5-min HR averages
from 18 participants, 4736 (91.4%) remained after exclusion of
charging times. From these, three datasets were made containing:
(1) raw data (all 4736 data points) (2) filtered data containing
<50% artifacts [4059 (85.5%) data points] (3) filtered data
containing <20% artifacts [3677 (77.6%) data points].
To analyze the strength of the linear relationship and
agreement between both devices, synchronized data from both
devices were analyzed with Pearson correlation analysis, and
Bland-Altman plots for all three datasets. To explore possible
determinants of artifacts, we stratified data based on sex, day,
and night, tertiles of waist: hip ratios, BMI, and tertiles of activity.
The artifact distribution in strata was compared using Chi-square
(X2) test. The association between BMI and artifact load was
assessed using linear regression.
The per-participant estimates of HR and HRV derived from
EQ02 and Holter monitors were compared with paired t-tests.
For all paired points, RD, ARD, and MARD were determined
using aforementioned formulae.
Graphs were drawn using GraphPad Prism version 5
(GraphPad, San Diego, CA). All statistical analyses were
performed using SPSS v.20 (SPPS Inc., Chicago, U.S.A.).
Two-sided p-values below 0.05 were considered statistically
significant.
RESULTS
Heart Rate
Characteristics of study participants are summarized in
Table 2 and described in detail per-person in Supplementary
Table 1. The mean age of the participants was 27.6 years
(range 19–57 years); 10 (55%) were males. The activity
TABLE 2 | Subject characteristics.
Demographics N = 18
Male n (%) 10 (55)
Age, years 27.6 (9.4)
Weight, kg 72 (10.2)
BMI, kg/m2 22.5 (2.4)
Waist: hip ratio 0.81 (0.1)
Sleep (mins) 580.2 (156)
Step counts (total in 24 h) 9635 (2916)
% Artifacts in raw EQ02 data* 19.0 (14.7)
Data represent mean with standard deviation unless stated otherwise.
*Excluding charging times.
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FIGURE 2 | Twenty four hour HR measurements by EQ02 and Holter. Hourly averages of HR measured simultaneously using the EQ02 and Holter monitors for
three participants (A–C). Raw EQ02 and automatically cleaned EQ02 data using the medium and high artifact sensitivity options of the Vivosense software are
displayed. Artifact percentages over 24 h (above each graph) and per hour (right y-axis) are presented.
pattern of the participants was variable, ranging from 5017
to 14,265 steps taken in 24 h. Medical history showed that
none of the participants had persistent chest pain, tiredness,
dyspnea, lightheadedness, palpitations, cardiovascular diseases,
hypertension, endocrine, or other diseases. Two participants
had hypothyroidism, for which they used levothyroxine
(data not shown).
Different components of the cardiac cycle, including p-waves
were clearly identifiable in the ECG tracings from both the EQ02
and Holter (Figure 1).
Artifact Management
As shown in Table 2, the average artifact percentage of the 24 h
EQ02 data was 19% (SD 14.7). However, marked differences
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existed in data quality (Supplementary Table 1) between
participants (range 1.93–56.45%) and within participants (range
0.75–99.61%). Individual 24 h graphs of Holter and EQ02 heart
rate measurements of each of the 18 participants are shown in
Supplementary Figure 1.
Figure 2 shows hourly averages of HR from the Holter, and
EQ02 before cleaning, and after medium and high sensitivity
cleaning for three representative participants with average artifact
percentages over 24 h of 1.93, 56.45, and 22.15% respectively.
Artifact percentages were variable throughout the day, but higher
just around charging times, and lowest at night. At lower artifact
percentages, there was good concordance between the EQ02
and Holter HR. In contrast, at higher artifacts percentages,
there was discordance between the EQ02 and Holter HR values
that persisted after applying the Vivosense automatic cleaning
methods.
In addition, 24 h EQ02 data for the participant in Figure 2C
was cleaned manually, which took 24 h. Manual cleaning did not
eliminate the discordance between Holter and EQ02 data at high
artifacts percentages.
EQ02 Sensor Performance
Figure 3 displays the Pearson correlation coefficients of HR
measured using EQ02 and Holter for the three datasets sorted on
artifact percentage. Pearson correlations were 0.724 for all data,
and 0.955 and 0.997 for the datasets containing <50 and <20%
artifacts respectively.
EQ02 Point Accuracy, Mean Accuracy, and Precision
Metrics
The point accuracy for EQ02 across the three datasets of varying
artifact percentages are shown as RD and ARD distributions in
Figures 4A,B. For all data, 2246 of 4542 (49%) paired RD points
had negative RD values. From the datasets containing <50%
artifacts and <20% artifacts, respectively, 1802 of the 3882 (46%)
and 1359 of the 3118 (43.6%) paired RD points had negative RD
values. From the distribution of RD and ARD values shown in
Figure 4, the distribution of the underestimation extended over a
broader range of HR values at higher artifact percentages.
As an indicator of mean accuracy and precision of the EQ02,
the MARD in EQ02 HR data relative to Holter HR over 24 h are
presented for the three data sets in Figure 4C. The 24 h MARD
was 7.08 ± 17% for all data, 3.01 ± 10.55% for data containing
<50% artifacts and 1.5 ± 10.51% for data containing <20%
artifacts. As depicted by the SD of the MARD, while the precision
did not markedly differ between <20% (SD = 10.51) or <50%
artifacts (SD = 10.55), precision decreased at >50% artifacts
(SD= 17).
Agreement between Devices
Bland-Altman plots of paired HR values from both devices are
presented in Figure 5, for the three datasets. Compared to the
Holter, HR was on average lower when derived from EQ02, with
respectively a mean (95% CI) difference of −2.8 (−29.8 to 24.3)
beats per minute (bpm) for all data, −1.0 (−16.1 to 14.14) bpm
for data <50% artifact and −0.8 (−13.5 to 11.8) bpm for data
<20% artifacts.
FIGURE 3 | Pearson correlations of HR measured by EQ02 and Holter.
Both R2 and Pearson correlation coefficients are shown for (A) all data, and
filtered data containing (B) <50% artifacts and (C) <20% artifacts.
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FIGURE 4 | Accuracy, precision, and reliability of the EQ02 HR measurements. The distribution, as a function of Holter values, of the relative difference (RD, A)
and absolute RD (B) between each EQ02 HR measurement and its corresponding Holter HR value, for all data, and filtered data containing <50% and <20% artifacts
respectively. (C): MARD between EQ02- and Holter- derived HR values.
Evaluation of Artifacts
In order to evaluate the artifact burden of the EQ02, we compared
the artifact content of 24 h Holter ECG recordings from 4143
subjects with raw EQ02 data from 200 subjects. The average
artifact percentage from the 4143 holter recordings was 2.95%,
whereas the average artifact percentage from the 200 EQ02
recordings was 12.76%. Thus, the mean difference in artifact
percentage in raw EQ02 compared to raw holter ECG was 10%.
For the Holter, 77.9% of the 4143 rawHolter ECG recordings had
artifact percentage of ≤5%, whereas 65.5% of the 200 raw EQ02
ECG recordings had artifact percentage of≤5%. The distribution
of the artifacts is presented in Figure 6.
Next, we evaluated possible sources of artifacts for the
EQ02 recordings, including sex, waist: hip ratio, daytime vs.
nighttime (during which participants were asleep), activity (step
counts) and BMI. The mean (SD) artifact percentages of male
participants [19.4% (11.4)] was not significantly different (P =
0.348) from that of females [15.9 (17.9)]. When participants
were divided into tertiles based on waist: hip ratio (w:h), tertile
1 (w:h range 0.71–0.76) had mean (SD) artifact percentage
of 7.5 (3.5); tertile 2 (w:h range 0.77–0.83) had mean (SD)
artifact percentage of 16.4 (6.0) while tertile 3 (w:h range
0.87–0.92) had mean (SD) artifact percentage of 29.7 (18.5)
(P = 0.014).
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FIGURE 5 | Bland-Altman plots of HR measured by EQ02 and Holter.
Each dot represent paired (EQ02-Holter) HR values derived from all
participants. The bias of the measurements (represented as solid lines) and the
± 1.96 SD (dotted lines) are presented for the measurements obtained for all
data (A), filtered data containing <50% (B) artifacts and <20% artifacts (C).
During the day, 62.9% of the data contained <20%
artifacts, 17.15% contained 20–50% artifacts and 19.9% had
50–100% artifacts. In contrast, during the night, 82.7% of
the data contained <20% artifacts, 12.4% contained 20–50%
artifacts whereas 4.9% had 50–100% artifacts. Thus, there
was considerably more artifacts during daytime compared to
nighttime (p < 0.001).
Furthermore, we also evaluated if activity of the participants,
as measured using number of step counts taken during the study,
had a bearing on artifacts percentage. Participants were divided
FIGURE 6 | Comparison of artifact content of raw Holter data to raw
EQ02 data. Bar chart showing content and distribution of artifact in raw
(uncleaned) 24 h Holter ECG recordings from 4143 subjects with raw EQ02
data from 200 subjects. The average artifact percentage from the holter
recordings was 2.95%, whereas the average artifact percentage from that 200
EQ02 recordings was 12.76%. AP: artifact percentage.
into tertiles based on step counts, representing low activity (tertile
1, with 5017–8228 steps), medium activity (tertile 2 with 8229–
11,439 steps), and high activity (tertile 3 with 11,440–14,265
steps) respectively. For tertile 1 (least active), 73.3% of the data
contained<20% artifacts, 11.8% contained 20–50% artifacts, and
14.9% of the data from the least active people contained 50–
100% artifacts. For tertile 2 (medium active), 66.2% of the data
contained<20% artifacts, 14.7% contained 20–50% artifacts, and
19.0% of the data contained 50–100% artifacts. Thus, there were
comparatively more artifacts in tertile 2 compared to tertile 1 (p
< 0.001). Similar significant result was obtained for comparison
of tertile 3 (most active) to tertile 1 (p < 0.001).
Finally, we assessed the association between BMI and artifact
percentage. No significant association was found between BMI
and artifact content of the EQ02 ECG recordings (P = 0.256),
data not shown.
Heart Rate Variability
Figure 7 graphically displays 10-min averages of different
HRV parameters for one participant (serial number 11, with
overall average artifact percentage of 5.23%). Comparing HRV
parameters from the two devices, the Pearson correlations were
0.967 for ANN, 0.393 for SDNN, 0.285 for rMSSD, 0.680 for
SDANN, and 0.982 for pNN50 for the 24-h data. However,
after selecting a 3-h stretch of data containing minimal artifacts
(1.15% artifacts), the Pearson correlation for ANN remained
the same. Except for pNN50 with Pearson correlation of 0.967
for 3-h data, the Pearson correlation coefficients of the other
HRV parameters improved to 0.786 for SDNN, 0.868 for rMSSD,
and 0.991 for SDANN for the 3 h data with minimal artifacts
(Figure 8).
DISCUSSION
The EQ02 is a wireless device which can be used for
monitoring multiple parameters, either real-time/live or
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FIGURE 7 | Twenty four hour EQ02 and Holter HRV profile. Average NN, SDNN, and rMMSD of a participant over 24 h, as recorded by the Holter (red) and EQ02
(blue).
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FIGURE 8 | Comparison between HRV parameters measured by EQ02 and Holter. Correlation between ANN, SDNN, RMSSD, and pNN50 in a participant
from both devices over 24 h (A–D) and in a sub-selection of 3-h data with artifact percentage of 1.15% (E–H).
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oﬄine/retrospectively. This is the first study to investigate
the accuracy of EQ02 for continuous ECG measurement by
comparing EQ02 with the gold standard (Holter). The major
findings of this study are: (1) EQ02 is a convenient device for
continuous measurement of ECG and its derivatives; (2) marked
differences were observed in data quality between and within
participants; (3) at lower artifacts percentages, HR, and HRV
measurements from EQ02 and Holter measurements were
highly correlated; (4) artifact percentages were lower during
nighttime, when waist: hip ratio was lower, and at lower activity/
movement levels, as measured by step counts taken during the
study.
EQ02 is relatively easy to wear in a home setting during
habitual activities due to the design of the belt system with
textile electrodes (the absence of wires). The use of wireless
fabric electrodes in the wearable belt provides comfort that
makes the system suitable for prolonged and/ or frequent
recordings (Yu-Hong et al., 2012). However, this also imposes a
limitation because textile electrodes are more prone to motion
artifacts which interfere with R-wave detection (Nangalia et al.,
2010). Since textile—based electrodes do not have adhesives
or clips, the instability and misplacement of the electrodes
can be a possible source of the relatively higher artifact
percentages that we observed for the ECG recordings from the
EQ02 monitor. This validation study found marked differences
in EQ02 data quality between and within participants, as
determined by the percentage of artifacts. We found more
artifacts just before EQ02 charging times. For this study, the
EQ02 was charged for 1 h for every 12 h of use. Removal
and replacement of the monitor around charging times is a
possible reason for the increased artifacts around charging
times. Known sources of artifacts for cardiac telemetric devices
include electrode movement with respect to the skin interface
(disrupting electrochemical equilibrium); muscle contraction
resulting in unwanted electromyographic contamination that
may share the desired signal frequency band; vocalizations;
temperature changes; sensor-cross-talk; optical path length
changes and electromagnetic induction (Nangalia et al., 2010; El-
Sherif and Turitto, 2015). In literature, artifact load of cardiac
telemetric devices have also been attributed to body movement,
temporary impairment of skin electrode contact, loose electrode
connections, broken leads, skeletal myopotentials, and ambient
noise (Brage et al., 2005). In line, we also found that higher
artifacts were found at higher activity levels, since this involves
increased body movement.
Previous studies have shown that when comparing
ambulatory electrocardiographic monitoring (AEM) devices,
artifacts were more common in telemetric recordings (Brage
et al., 2005). When comparing artifact content of the raw
EQ02 data to raw Holter data, we found that the difference
was 10%. This is higher than the difference of 4.8% higher
artifacts that have been reported for other AEMs (Brage
et al., 2005), although the comparisons of artifact percentage
in previous studies are based on rate of misdetection of
arrhythmias. The artifact comparison in the present study
was based on artifact content of raw ECG signals from both
devices.
The Vivosense software offers three artifact-cleaning options.
These are based on the assumption that physiological changes
will occur slowly over several beats, whilst artifacts may result in
sudden or more rapid changes or non-physiological variability
in inter-beat interval timing. Vivosense therefore re-samples
and smooths the R-R time series and compares the smoothed
waveform with the actual RR waveform. Thresholds are set based
on the “low, medium, and high” settings that govern the degree
of allowable variance between the two waveforms. Any beat
that deviates significantly from the smoothed range is flagged as
potential artifact.
We demonstrated that at low artifact percentages, EQ02
can be used to reliably monitor ECG and its derivatives (HR,
HRV) in relatively healthy participants. This is in accordance
with a previous study (Liu et al., 2013) that compared HR
derived from EQ02 and Polar S810i HR monitors under 10 min
each of standing, lying and sitting. However, at higher artifact
percentages (50% and higher), we found discordance between
the EQ02 and Holter, which did not improve after application
of the automatic cleaning options provided by Vivosense.
Correlations improved by selecting data with <50% artifact or
<20% artifacts. Similarly, HRV parameters (SDNN, RMSSD,
and pNN50) also showed markedly improved correlations after
selection on a 3-h stretch of data with minimal artifacts. This
further strengthens the finding that the quality of EQ02 is best
at low artifact percentages. This agrees well with observations
made by investigations into other mobile devices (Haberman
et al., 2015). For example, a validation study of the Actiheart
found that HR values from Actiheart were in good agreement
with those of other HRmonitors during rest, but errors increased
during exercises of higher intensity (Haberman et al., 2015).
During high intensity movements, mobile devices are more
prone to artifacts, in comparison to during rest. In line, whilst
investigating potential determinants of artifacts, we found that
artifact percentages were lower at lower activity levels (fewer
step counts), at night, in subjects with lower waist: hip ratio
and also somewhat lower in females. At night, participants
were lying supine and mostly asleep which might result in
better contact with electrodes and/ or decreased movement.
Participants with lower waist: hip ratio also had significantly
lower artifact percentages possibly because of better fitting of
the Equivital belt. This could also have been the case in females,
since female participants wore an extra layer of underwear over
the Equivital belt, which might have potentially reduced belt
displacements. This suggest that the artifact content of the EQ02
were most likely attributable to motion artifacts and/or impaired
skin-electrode contact.
One main limitation of our study is that it was conducted
in eighteen relatively healthy participants without overt cardiac
disease. A strength was that ECG was measured continuously
and simultaneously using both devices over 24 h. More studies
are needed to validate the EQ02 in specific groups, such as
in the elderly, in large population studies and in patients with
known cardiac disease. However, the susceptibility of the EQ02
to artifacts should be taken into account in such studies. Before
application of Holter monitors, skin preparation is normally
done with alcohol/KCl, and red dot to remove non-conductive
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skin layer and reduce skin impedance to minimize artifacts.
Perhaps employing skin preparation techniques could also aid in
minimizing artifacts with EQ02 recordings.
Summarily, we compared continuous ECG from EQ02 to the
Holter over 24 h. Skin preparation, as well as clips used before
application of the Holter electrodes prevents artifacts, whereas
artifact management of EQ02 was done after data acquisition.
We found that there was, on average, good agreement between
HR and HRV values derived from EQ02 and Holter. However, its
accuracy and reliability depended on the presence and quantity
of artifacts. Presently, the artifact load of EQ02’s ECG recordings
exceeds that of the Holter. This would pose a serious limitation to
its clinical use in individual patients, especially for measurements
that are especially sensitive to artifacts. On the other hand, if
artifacts can be properly managed, the EQ02’s ability to monitor
(live and/or retrospective), synchronize and store cardiac and
other physiological parameters may offer potential benefits for
home monitoring and/ or research purposes, as it could be useful
for extensive continuous recording of ECG, HR, HRV and other
physiologic data in large population studies.
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